Benefits of oral Polypodium Leucotomos extract in MM high-risk patients

Background: UV radiation and the presence of melanocytic nevi are the main risk factors of sporadic melanoma (MM). Protection of skin by an oral photoprotective agent would have substantial benefits. Objective: We investigated the possible role of an oral Polypodium leucotomos (PL) extract to improv...

Full description

Bibliographic Details
Authors: Aguilera, Paula, Carrera Álvarez, Cristina, Puig Butillé, Joan Anton, Badenas Orquin, Celia, Lecha, M., González, Salvador, Malvehy, J. (Josep), Puig i Sardà, Susana
Format: article
Status:Versión aceptada para publicación
Publication Date:2012
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/178121
Online Access:https://hdl.handle.net/2445/178121
Access Level:Open access
Keyword:Melanoma
Càncer de pell
Skin cancer
id ES_1154a09a0e22ae324d00e46cdd236f93
oai_identifier_str oai:diposit.ub.edu:2445/178121
network_acronym_str ES
network_name_str España
repository_id_str
spelling Benefits of oral Polypodium Leucotomos extract in MM high-risk patientsAguilera, PaulaCarrera Álvarez, CristinaPuig Butillé, Joan AntonBadenas Orquin, CeliaLecha, M.González, SalvadorMalvehy, J. (Josep)Puig i Sardà, SusanaMelanomaCàncer de pellMelanomaSkin cancerBackground: UV radiation and the presence of melanocytic nevi are the main risk factors of sporadic melanoma (MM). Protection of skin by an oral photoprotective agent would have substantial benefits. Objective: We investigated the possible role of an oral Polypodium leucotomos (PL) extract to improve systemic photoprotection in patients at risk of skin cancer analyzing the ability to decrease UV‐induced erythema. We also studied the interaction among MC1R polymorphisms and CDKN2A status with the minimal erythematous dose (MED) and their influence in the response after oral PL. Methods: A total of 61 patients (25 with familial and/or multiple MM, 20 with sporadic MM and 16 with atypical mole syndrome without history of MM) were exposed to varying doses of artificial UVB radiation without and after oral administration of a total dose of 1080mg of PL. Results: Oral PL treatment significantly increased the MED mean in all group patients (0.123 to 0.161 J/cm2, p<0.05). Although not significant, we noticed a stronger effect of PL on the MED of patients with familial MM compared to those with MM (U=273, p=0.06). Among the patients with familial MM, those exhibiting a mutated CDKN2A and/or polymorphisms in MC1R had the bigger differences in response to treatment with PL. Limitations: Reduced number of patients. No control population. Conclusions: Administration of PL leads to a significant reduction of sensitivity to UVR (p<0.05) in all patients. Dark‐eye patients and patients with higher UVR sensibility (lower basal MED) would be the most benefited from oral PL treatment.Wiley2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/178121Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1111/j.1468-3083.2012.04659.xJournal of the European Academy of Dermatology and Venereology, 2012, vol. 27, num. 9, p. 1095-1100https://doi.org/10.1111/j.1468-3083.2012.04659.x(c) European Academy of Dermatology and Venereology, 2012info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1781212026-05-27T06:46:51Z
dc.title.none.fl_str_mv Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
title Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
spellingShingle Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
Aguilera, Paula
Melanoma
Càncer de pell
Melanoma
Skin cancer
title_short Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
title_full Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
title_fullStr Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
title_full_unstemmed Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
title_sort Benefits of oral Polypodium Leucotomos extract in MM high-risk patients
dc.creator.none.fl_str_mv Aguilera, Paula
Carrera Álvarez, Cristina
Puig Butillé, Joan Anton
Badenas Orquin, Celia
Lecha, M.
González, Salvador
Malvehy, J. (Josep)
Puig i Sardà, Susana
author Aguilera, Paula
author_facet Aguilera, Paula
Carrera Álvarez, Cristina
Puig Butillé, Joan Anton
Badenas Orquin, Celia
Lecha, M.
González, Salvador
Malvehy, J. (Josep)
Puig i Sardà, Susana
author_role author
author2 Carrera Álvarez, Cristina
Puig Butillé, Joan Anton
Badenas Orquin, Celia
Lecha, M.
González, Salvador
Malvehy, J. (Josep)
Puig i Sardà, Susana
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Melanoma
Càncer de pell
Melanoma
Skin cancer
topic Melanoma
Càncer de pell
Melanoma
Skin cancer
description Background: UV radiation and the presence of melanocytic nevi are the main risk factors of sporadic melanoma (MM). Protection of skin by an oral photoprotective agent would have substantial benefits. Objective: We investigated the possible role of an oral Polypodium leucotomos (PL) extract to improve systemic photoprotection in patients at risk of skin cancer analyzing the ability to decrease UV‐induced erythema. We also studied the interaction among MC1R polymorphisms and CDKN2A status with the minimal erythematous dose (MED) and their influence in the response after oral PL. Methods: A total of 61 patients (25 with familial and/or multiple MM, 20 with sporadic MM and 16 with atypical mole syndrome without history of MM) were exposed to varying doses of artificial UVB radiation without and after oral administration of a total dose of 1080mg of PL. Results: Oral PL treatment significantly increased the MED mean in all group patients (0.123 to 0.161 J/cm2, p<0.05). Although not significant, we noticed a stronger effect of PL on the MED of patients with familial MM compared to those with MM (U=273, p=0.06). Among the patients with familial MM, those exhibiting a mutated CDKN2A and/or polymorphisms in MC1R had the bigger differences in response to treatment with PL. Limitations: Reduced number of patients. No control population. Conclusions: Administration of PL leads to a significant reduction of sensitivity to UVR (p<0.05) in all patients. Dark‐eye patients and patients with higher UVR sensibility (lower basal MED) would be the most benefited from oral PL treatment.
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/178121
url https://hdl.handle.net/2445/178121
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1111/j.1468-3083.2012.04659.x
Journal of the European Academy of Dermatology and Venereology, 2012, vol. 27, num. 9, p. 1095-1100
https://doi.org/10.1111/j.1468-3083.2012.04659.x
dc.rights.none.fl_str_mv (c) European Academy of Dermatology and Venereology, 2012
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) European Academy of Dermatology and Venereology, 2012
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403558991888384
score 15.198674

Similar Items